Ad Scientiam, a French medtech company and reference in digital solutions for clinical data collection through smartphone-based technology, announces that TechLife Capital, a growth-capital fund specialized in health technologies, has joined its shareholding.

Founded in 2013, Ad Scientiam develops digital medical solutions that enable the collection and analysis of patient data through smartphone-based tools. These tools, approved as medical devices, aim to convert measured signals into digital biomarkers capable of replacing traditional clinical-trial methods.

Ad Scientiam became known in 2019 with MSCopilot, the first CE-marked software medical device allowing patient self-assessment in multiple sclerosis. The company is now extending its work to other pathologies in neuroscience, rare diseases and mental-health disorders.

TechLife Capital’s backing will enable Ad Scientiam to pursue technological investments,accelerate the diversification of its therapeutic indications, consolidate its position as a European leader in digital medicine, enhance its impact in patient monitoring, and deploy its solutions internationally.